Valeant to Borrow About $7 Billion for Bausch & Lomb Buyout
Stock Chart for Valeant Pharmaceuticals International Inc (VRX)
Valeant Pharmaceuticals International Inc. (VRX) said it secured debt financing from Goldman Sachs Group Inc. for $6.7 billion to $7.2 billion for its buyout of Bausch & Lomb Holdings Inc. Montreal-based Valeant will pay $4.5 billion for the eye-care company and spend $4.2 billion to repay Bausch & Lomb’s debt, the companies said in a statement. The deal will bring Valeant’s debt as a ratio of earnings before interest, taxes, depreciation and amortization to 4.6 times, according to the statement.
To contact the editor responsible for this story: Cecile Gutscher at email@example.com
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.